Number of the records: 1  

Amphiphilic compounds with neuroprotective properties

  1. 1.
    SYSNO ASEP0519500
    Document TypeP - Patent
    R&D Document TypePatent or other outcome protected by special legislation
    TitleAmphiphilic compounds with neuroprotective properties
    Author(s) Kudová, Eva (UOCHB-X) RID, ORCID
    Chodounská, Hana (UOCHB-X) RID, ORCID
    Kapras, Vojtěch (UOCHB-X)
    Vyklický ml., Ladislav (FGU-C) RID, ORCID, SAI
    Valeš, Karel (FGU-C) RID, ORCID, SAI
    Jahn, Ullrich (UOCHB-X) ORCID
    Year of issue2019
    Possible third party use of the resultA - Pro využití výsledku jiným subjektem je vždy nutné nabytí licence
    Royalty requestedA - Poskytovatel licence požaduje licenční poplatek
    Patent no. or utility model no. or industrial design no.EP3260462
    Date of the patent acceptance17.04.2019
    Name of the patent ownerÚstav organické chemie a biochemie AV ČR, v. v. i. - Fyziologický ústav AV ČR, v. v. i
    Code of the issuer nameEPO_1 - European Patent Office Munich, The Hague, Berlin, Vienna, Brusselshttp://www.epo.org/
    Current useA - Pouze udělený (dosud nevyužívaný) patent nebo patent využívaný jeho vlastníkem
    Languageeng - English
    Keywordssteroid ; NMDA receptor ; neuroprotective
    Subject RIVCC - Organic Chemistry
    OECD categoryOrganic chemistry
    Subject RIV - cooperationInstitute of Physiology - Pharmacology ; Medidal Chemistry
    R&D ProjectsTE01020028 GA TA ČR - Technology Agency of the Czech Republic (TA ČR)
    GBP304/12/G069 GA ČR - Czech Science Foundation (CSF)
    Institutional supportUOCHB-X - RVO:61388963 ; FGU-C - RVO:67985823
    AnnotationThe present invention provides amphiphilic compounds with a tetradecahydrophenanthrene skeleton of formula (I), wherein R1-R5 are as defined herein, and their enantiomers, exhibiting neuroprotective effects, for use as medicaments for treating neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain , addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing said compound.
    WorkplaceInstitute of Organic Chemistry and Biochemistry
    Contactasep@uochb.cas.cz ; Kateřina Šperková, Tel.: 232 002 584 ; Jana Procházková, Tel.: 220 183 418
    Year of Publishing2020
    Electronic addresshttps://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20190417&DB=&locale=en_EP&CC=EP&NR=3260462B1&KC=B1&ND=5#
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.